From bench to IND: Validation of TSLPR CAR T-cells reveal discrepancies in detection modalities and inform dose selection for a Phase 1 clinical trial in relapsed/refractory CRLF2-rearranged B-ALL patients.
Year: 2025
Type: conference-abstract
Source: Blood
Institutions: National Institutes of Health, National Cancer Institute, National Institutes of Health Clinical Center, Lentigen Technology (United States), Children's Hospital of Philadelphia, Abramson Cancer Center, University of Pennsylvania, University of Colorado Anschutz, University of Colorado Denver
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417022173
Cites:
Cited by:
Related to: